Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 16/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20876286 | 0.77 | SLC6A4 (0.40) | SLC6A4SLC6A3SLC6A2OPRM1 | |
| SCHEMBL15043671 | 0.77 | SLC6A4 (0.50) | SLC6A4SLC6A3SLC6A2KCNH2CYP2D6 | |
| SCHEMBL19767368 | 0.74 | SLC6A4 (0.56) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL19772413 | 0.74 | SLC6A4 (0.56) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL19772416 | 0.74 | SLC6A4 (0.56) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL625336 | 0.73 | SLC6A4 (0.50) | SLC6A4SLC6A3SLC6A2KCNH2 | |
| SCHEMBL15873672 | 0.73 | SLC6A4 (0.50) | SLC6A4SLC6A3SLC6A2KCNH2CYP2D6 | |
| SCHEMBL15863260 | 0.73 | SLC6A4 (0.50) | SLC6A4SLC6A3SLC6A2KCNH2CYP2D6 | |
| SCHEMBL14625431 | 0.72 | SLC6A4 (0.50) | SLC6A4SLC6A3SLC6A2KCNH2 | |
| SCHEMBL3516295 | 0.72 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200267977-A1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| EP-3692019-A1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | Syngenta Participations AG (CH) | 2020-08-12 | — | — | EP | disclosed |
| CN-111183133-A | Microbicidal picolinamide derivatives | 先正达参股股份有限公司 | 2020-05-19 | — | — | CN | disclosed |
| WO-2019068812-A1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200267977-A1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | PRF1, CASP1, FPR1 | SLC6A4 3476/4885SLC6A3 3866/4885SLC6A2 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.